Valuation: Intervacc AB

Market Cap 397M 41.02M 35.95M 33.23M 30.57M 57.67M 3.96B 58.6M 156M 1.94B 154M 151M 6.67B P/E 2026 *
-5.3x
P/E 2027 * -5.3x
Enterprise Value 304M 31.42M 27.54M 25.46M 23.41M 44.17M 3.03B 44.88M 119M 1.48B 118M 115M 5.11B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 11.1x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week-10.48%
Current month-10.89%
1 month-12.10%
3 months-3.17%
6 months+29.69%
Current year+25.76%
1 week 1.14
Extreme 1.14
1.3
1 month 1.14
Extreme 1.14
1.36
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
84
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
2/23/25 A Free

Chief Financial Officer

929,208 1.2269%
2/17/25 A Sell

Chief Executive Officer

278,820 0.3681%
2/17/25 A Buy

Chief Executive Officer

135,000 0.1783%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-10.48%+17.37%-76.04% 41.23M
+0.21%-0.79%+56.02%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
+0.12%-0.62%+5.53%+409.46% 23.48B
+0.89%+2.20%-15.48%-14.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-2.97%+32.73%-33.30% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
+0.33%+0.36%+27.07%+183.04% 14.06B
Average +1.10%-3.28%+40.13%+155.29% 23.36B
Weighted average by Cap. +1.70%-2.35%+42.64%+140.24%

Financials

2026 *2027 *
Net sales 17.7M 1.83M 1.6M 1.48M 1.36M 2.57M 176M 2.61M 6.94M 86.21M 6.86M 6.71M 297M 30.05M 3.1M 2.72M 2.51M 2.31M 4.36M 299M 4.43M 11.78M 146M 11.65M 11.39M 504M
Net income -80.8M -8.34M -7.31M -6.76M -6.21M -11.73M -804M -11.91M -31.67M -394M -31.32M -30.64M -1.36B -83.65M -8.63M -7.57M -7M -6.43M -12.14M -833M -12.33M -32.79M -407M -32.42M -31.72M -1.4B
Net Debt -93M -9.6M -8.41M -7.78M -7.15M -13.5M -926M -13.71M -36.46M -453M -36.05M -35.26M -1.56B -63M -6.5M -5.7M -5.27M -4.85M -9.14M -627M -9.29M -24.7M -307M -24.42M -23.89M -1.06B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
20/07/26 SEK 1.162 -0.34% 206,488
17/07/26 SEK 1.166 -3.80% 370,510
16/07/26 SEK 1.212 -3.04% 146,658
15/07/26 SEK 1.250 -1.42% 108,813
14/07/26 SEK 1.268 -2.31% 257,239

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock